Mylan Nv Ord Shs

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%



Code Company Date Close Change Indicator Value Signal

Trading Performance

Average True Range



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 7 61.7 0.29% 0.40% 3.5% -14.5% -65.5%
SHORT 6 48.7 0.33% 0.50% 8.8% -3.2% 4.8%


Technical Analysis

Mylan Nv Ord Shs has a TR of 0.47, and an ATR(14) of 0.638.

Average true range (ATR) is a technical analysis volatility indicator originally developed by J. Welles Wilder Jr. for commodities. The indicator does not provide an indication of price trend simply the degree of price volatility.

Calculation: Average True Range (ATR):
1) Current ATR = [(Prior ATR x 13) + Current TR] / 14;
2) Where TR = max[(high-low) abs(high-close previous) abs (low-close previous)]

PROFILE: Mylan Nv Ord Shs (MYL)

Stock Exchange: NASDAQ
Company: Mylan Nv Ord Shs
Ticker Codes: | MYL | NASDAQ:MYL |

About Mylan Nv Ord Shs (NASDAQ:MYL):

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Top 10:

Average True Range

Company Close Change(%) Volume Value Signal
CTMX CytomX Therapeutics 6.18 19.3 1,006,973 0.9 NEUTRAL
AVDL Avadel Pharmaceuticals 5.52 14.8 836,617 2.77 NEUTRAL
PACB Pacific Biosciences 5.21 11.1 6,938,579 0.54 NEUTRAL
UEPS Net 1 UEPS Technologies 3.56 10.9 686,631 0.36 NEUTRAL
CRIS Curis Inc 1.53 10.1 293,610 0.59 NEUTRAL
VRAY Viewray Inc 3.09 6.6 3,315,227 0.98 NEUTRAL
ACIU AC Immune 7.88 5.6 120,113 0.43 NEUTRAL
CLDX Celldex Therapeutics 2.24 5.2 200,265 0.15 NEUTRAL
NH Nanthealth 1.08 4.9 538,802 0.37 NEUTRAL
ATRS Antares Pharma 4.65 4.7 2,999,741 0.06 NEUTRAL